Detalhe da pesquisa
1.
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
Eur J Haematol
; 112(5): 776-787, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38226781
2.
High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.
Eur J Haematol
; 111(3): 400-406, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37286366
3.
Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study.
Br J Haematol
; 193(1): 83-92, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33169852
4.
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Haematologica
; 105(9): 2262-2272, 2020 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33054051
5.
Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
Ann Hematol
; 98(1): 101-109, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30182347
6.
B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.
Eur J Haematol
; 103(4): 351-361, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31297883
7.
Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Eur J Haematol
; 98(1): 75-84, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27471124
8.
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Blood Cancer J
; 14(1): 28, 2024 02 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38331919
9.
Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.
Int J Cardiol
; 364: 112-118, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35716942
10.
[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases].
Ugeskr Laeger
; 183(42)2021 10 18.
Artigo
Dinamarquês
| MEDLINE | ID: mdl-34709157
11.
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Cancer Med
; 7(8): 3571-3581, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29932310
12.
Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.
Leuk Res
; 41: 27-35, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26718091
13.
Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?
Leuk Lymphoma
; 57(8): 1793-9, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-26879691
14.
A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate.
Leuk Res Rep
; 6: 20-3, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27489765